Belzutifan for the treatment of renal cell carcinoma
Belzutifan received its first FDA approval in 2021 for treating clinical manifestations of von Hippel-Lindau (VHL) disease including renal cell carcinoma (RCC) followed by approval in 2023 for treating advanced sporadic RCC that has progressed through multiple lines of treatment. It is the first FDA...
Saved in:
Main Authors: | Xiancheng Wu, David Lazris, Risa Wong, Scott S. Tykodi |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-02-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359251317846 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tumor-initiating and metastasis-initiating cells of clear-cell renal cell carcinoma
by: Dinh-Xuan Pham, et al.
Published: (2025-02-01) -
Tubulocystic renal cell carcinoma: Case report and literature review
by: Yun-Shen Ding, et al.
Published: (2025-03-01) -
Application of Intraoperative Ultrasound in Robot-assisted Thrombectomy for Renal Cell Carcinoma
by: Zhu Jianing, Li Nan, Luo Yukun, Li Qiuyang
Published: (2025-03-01) -
Spontaneous Rupture of Renal Cell Carcinoma in Pregnancy: A Case Report
by: Mohamed Zakieldahshoury, et al.
Published: (2023-08-01) -
Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)